Ascendia is a specialty pharmaceutical company dedicated to developing enhanced formulations of existing drug products, as well as enabling formulations for NCE drug candidates. Ascendia provides state-of-the-art CDMO services for poorly water-soluble molecules, along with cGMP manufacturing of sterile and non-sterile products. Applying its nano-particle technologies and expertise, Ascendia can rapidly assess the feasibility of a broad array of formulation options in order to improve drug bioavailability. Proprietary technologies include nano-emulsions, amorphous solid dispersions, oral controlled release, and polymeric or lipid nanoparticles. Ascendia provides development and testing services – from early discovery through to late-stage cGMP manufacture of clinical supplies.